Origins of MCL genes

Tier 1 MCL genes

Gene Status First MCL study Other lists
ATM MCL Tier 1 Bea et al DLBCL, MZL
BIRC3 MCL Tier 1 Bea et al DLBCL, MZL, PMBL
CARD11 MCL Tier 1 Wu et al DLBCL, MZL, FL, BL
CCND1 MCL Tier 1 Bea et al
DAZAP1 MCL Tier 1 Pararajalingam et al DLBCL
EWSR1 MCL Tier 1 Pararajalingam et al PMBL
HNRNPH1 MCL Tier 1 Pararajalingam et al DLBCL
KMT2D MCL Tier 1 Bea et al FL, BL, DLBCL, PMBL, MZL
MEF2B MCL Tier 1 Bea et al FL, DLBCL
NFKBIE MCL Tier 1 Pararajalingam et al DLBCL, PMBL
NOTCH1 MCL Tier 1 Bea et al MZL, DLBCL, BL
NOTCH2 MCL Tier 1 Bea et al MZL, DLBCL
NSD2 MCL Tier 1 Bea et al DLBCL
POT1 MCL Tier 1 Zhang et al
RB1 MCL Tier 1 Zhang et al DLBCL
S1PR1 MCL Tier 1 Pararajalingam et al DLBCL
SMARCA4 MCL Tier 1 Nadeu et al DLBCL, BL, FL, PMBL
SP140 MCL Tier 1 Bea et al
SYNE1 MCL Tier 1 Nadeu et al
TERT MCL Tier 1 Nadeu et al
TLR2 MCL Tier 1 Bea et al DLBCL
TP53 MCL Tier 1 Bea et al PMBL, DLBCL, FL, BL, MZL
UBR5 MCL Tier 1 Pararajalingam et al DLBCL

Tier 2 MCL genes

Gene Status First MCL study Other lists
ABCA3 MCL Tier 2 Bea et al 1
ABCC9 MCL Tier 2 Bea et al
ANK2 MCL Tier 2 Zhang et al 1
ARID1B MCL Tier 2
ATP11C MCL Tier 2 Zhang et al
B2M MCL Tier 2 Pararajalingam et al 2,3
BCOR MCL Tier 2 Nadeu et al 4
CDH8 MCL Tier 2 Zhang et al 5
CHMP4C MCL Tier 2 Bea et al
COL11A1 MCL Tier 2 Zhang et al
COL16A1 MCL Tier 2 Zhang et al
CRYBG3 MCL Tier 2 Bea et al
CTNNA2 MCL Tier 2 Zhang et al
DCP1B MCL Tier 2 Bea et al
DHDH MCL Tier 2 Zhang et al
DLC1 MCL Tier 2 Zhang et al
DLGAP2 MCL Tier 2 Bea et al
DNAJC6 MCL Tier 2 Bea et al
EIF2AK4 MCL Tier 2 Zhang et al
ESX1 MCL Tier 2 Zhang et al
FAT4 MCL Tier 2 Zhang et al 6,7
GRIN2A MCL Tier 2 Zhang et al
HEPH MCL Tier 2 Zhang et al
KCNC2 MCL Tier 2 Bea et al
KIAA1671 MCL Tier 2 Bea et al
KMT2C MCL Tier 2 Zhang et al 1,8,9
LUZP4 MCL Tier 2 Bea et al
MRGPRF MCL Tier 2 Zhang et al
NIN MCL Tier 2 Zhang et al
OGDHL MCL Tier 2 Zhang et al
PCDHB2 MCL Tier 2 Zhang et al
PCSK2 MCL Tier 2 Bea et al
PDLIM3 MCL Tier 2 Bea et al
PLXNB3 MCL Tier 2 Zhang et al 10
RGS4 MCL Tier 2 Bea et al
ROBO2 MCL Tier 2 Zhang et al
SALL3 MCL Tier 2 Zhang et al 11
SI MCL Tier 2 Zhang et al
SLC17A6 MCL Tier 2 Bea et al
SMARCB1 MCL Tier 2 Nadeu et al
SMC1A MCL Tier 2 Zhang et al
TBC1D26 MCL Tier 2 Zhang et al
TNRC6B MCL Tier 2 Bea et al
TRPM6 MCL Tier 2 Bea et al
ZNF117 MCL Tier 2 Zhang et al
ZNF296 MCL Tier 2 Zhang et al

References

1.
Zhang J, Grubor V, Love CL, Banerjee A, Richards KL, Mieczkowski PA, Dunphy C, Choi W, Au WY, Srivastava G, Lugar PL, Rizzieri DA, Lagoo AS, Bernal-Mizrachi L, Mann KP, Flowers C, Naresh K, Evens A, Gordon LI, Czader M, Gill JI, Hsi ED, Liu Q, Fan A, Walsh K, Jima D, Smith LL, Johnson AJ, Byrd JC, Luftig MA, Ni T, Zhu J, Chadburn A, Levy S, Dunson D, Dave SS. Genetic heterogeneity of diffuse large B-cell lymphoma. Proceedings of the National Academy of Sciences of the United States of America. 2013;110:1398–1403. PMCID: PMC3557051
2.
Morin RD, Mendez-Lago M, Mungall AJ, Goya R, Mungall KL, Corbett RD, Johnson NA, Severson TM, Chiu R, Field M, Jackman S, Krzywinski M, Scott DW, Trinh DL, Tamura-Wells J, Li S, Firme MR, Rogic S, Griffith M, Chan S, Yakovenko O, Meyer IM, Zhao EY, Smailus D, Moksa M, Chittaranjan S, Rimsza L, Brooks-Wilson A, Spinelli JJ, Ben-Neriah S, Meissner B, Woolcock B, Boyle M, McDonald H, Tam A, Zhao Y, Delaney A, Zeng T, Tse K, Butterfield Y, Birol I, Holt R, Schein J, Horsman DE, Moore R, Jones SJM, Connors JM, Hirst M, Gascoyne RD, Marra MA. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature. 2011 Jul 27;476(7360):298–303. PMCID: PMC3210554
3.
Reichel J, Chadburn A, Rubinstein PG, Giulino-Roth L, Tam W, Liu Y, Gaiolla R, Eng K, Brody J, Inghirami G, Carlo-Stella C, Santoro A, Rahal D, Totonchy J, Elemento O, Cesarman E, Roshal M. Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-Sternberg cells. Blood. 2015 Feb 12;125(7):1061–1072.
4.
Jallades L, Baseggio L, Sujobert P, Huet S, Chabane K, Callet-Bauchu E, Verney A, Hayette S, Desvignes JP, Salgado D, Levy N, Béroud C, Felman P, Berger F, Magaud JP, Genestier L, Salles G, Traverse-Glehen A. Exome sequencing identifies recurrent BCOR alterations and the absence of KLF2, TNFAIP3 and MYD88 mutations in splenic diffuse red pulp small B-cell lymphoma. Haematologica. 2017 Oct;102(10):1758–1766. PMCID: PMC5622860
5.
Reddy A, Zhang J, Davis NS, Moffitt AB, Love CL, Waldrop A, Leppa S, Pasanen A, Meriranta L, Karjalainen-Lindsberg ML, Nørgaard P, Pedersen M, Gang AO, Høgdall E, Heavican TB, Lone W, Iqbal J, Qin Q, Li G, Kim SY, Healy J, Richards KL, Fedoriw Y, Bernal-Mizrachi L, Koff JL, Staton AD, Flowers CR, Paltiel O, Goldschmidt N, Calaminici M, Clear A, Gribben J, Nguyen E, Czader MB, Ondrejka SL, Collie A, Hsi ED, Tse E, Au-Yeung RKH, Kwong YL, Srivastava G, Choi WWL, Evens AM, Pilichowska M, Sengar M, Reddy N, Li S, Chadburn A, Gordon LI, Jaffe ES, Levy S, Rempel R, Tzeng T, Happ LE, Dave T, Rajagopalan D, Datta J, Dunson DB, Dave SS. Genetic and Functional Drivers of Diffuse Large B Cell Lymphoma. Cell. 2017 Oct;171(2):481–494.e15. PMCID: PMC5659841
6.
Morin RD, Mungall K, Pleasance E, Mungall AJ, Goya R, Huff RD, Scott DW, Ding J, Roth A, Chiu R, Corbett RD, Chan FC, Mendez-Lago M, Trinh DL, Bolger-Munro M, Taylor G, Hadj Khodabakhshi A, Ben-Neriah S, Pon J, Meissner B, Woolcock B, Farnoud N, Rogic S, Lim EL, Johnson NA, Shah S, Jones S, Steidl C, Holt R, Birol I, Moore R, Connors JM, Gascoyne RD, Marra MA. Mutational and structural analysis of diffuse large B-cell lymphoma using whole-genome sequencing. Blood. 2013 Aug 15;122(7):1256–1265. PMCID: PMC3744992
7.
Parry M, Rose-Zerilli MJJ, Gibson J, Ennis S, Walewska R, Forster J, Parker H, Davis Z, Gardiner A, Collins A, Oscier DG, Strefford JC. Whole exome sequencing identifies novel recurrently mutated genes in patients with splenic marginal zone lymphoma. PLoS One. 2013;8(12):e83244. PMCID: PMC3862727
8.
Sarkozy C, Hung SS, Chavez EA, Duns G, Takata K, Chong LC, Aoki T, Jiang A, Miyata-Takata T, Telenius A, Slack GW, Molina TJ, Ben-Neriah S, Farinha P, Dartigues P, Damotte D, Mottok A, Salles GA, Casasnovas RO, Savage KJ, Laurent C, Scott DW, Traverse-Glehen A, Steidl C. Mutational landscape of gray zone lymphoma. Blood. 2021 Apr 1;137(13):1765–1776.
9.
Zhou P, Blain AE, Newman AM, Zaka M, Chagaluka G, Adlar FR, Offor UT, Broadbent C, Chaytor L, Whitehead A, Hall A, O’Connor H, Van Noorden S, Lampert I, Bailey S, Molyneux E, Bacon CM, Bomken S, Rand V. Sporadic and endemic Burkitt lymphoma have frequent FOXO1 mutations but distinct hotspots in the AKT recognition motif. Blood Adv. 2019 Jul 23;3(14):2118–2127. PMCID: PMC6650741
10.
Spina V, Khiabanian H, Messina M, Monti S, Cascione L, Bruscaggin A, Spaccarotella E, Holmes AB, Arcaini L, Lucioni M, Tabbò F, Zairis S, Diop F, Cerri M, Chiaretti S, Marasca R, Ponzoni M, Deaglio S, Ramponi A, Tiacci E, Pasqualucci L, Paulli M, Falini B, Inghirami G, Bertoni F, Foà R, Rabadan R, Gaidano G, Rossi D. The genetics of nodal marginal zone lymphoma. Blood. 2016 Sep 8;128(10):1362–1373. PMCID: PMC5016706
11.
Love C, Sun Z, Jima D, Li G, Zhang J, Miles R, Richards KL, Dunphy CH, Choi WWL, Srivastava G, Lugar PL, Rizzieri DA, Lagoo AS, Bernal-Mizrachi L, Mann KP, Flowers CR, Naresh KN, Evens AM, Chadburn A, Gordon LI, Czader MB, Gill JI, Hsi ED, Greenough A, Moffitt AB, McKinney M, Banerjee A, Grubor V, Levy S, Dunson DB, Dave SS. The genetic landscape of mutations in Burkitt lymphoma. Nat Genet. 2012 Dec;44(12):1321–1325. PMCID: PMC3674561

Citing

If you use the information or data from this site, please cite

Krysta Coyle, Kostiantyn Dreval, Daniel Hodson and Ryan D. Morin. Audit of B-cell cancer genes. Blood Adv (2025) 9 (8): 2019–2031.

Disclaimer

The content in these pages has been populated, in part, by an automated process. Although we have scrutinized every page to ensure accuracy, errors will inevitably exist. If you find an error please report it as an issue and we will address it.

License

This work is licensed under a Creative Commons Attribution 4.0 International License.

You are free to:

Share — copy and redistribute the material in any medium or format for any purpose, even commercially.

Adapt — remix, transform, and build upon the material for any purpose, even commercially. The licensor cannot revoke these freedoms as long as you follow the license terms.